10058-F4 (SKU A1169): Reliable c-Myc-Max Dimerization Inh...

Inconsistent results in cell viability and apoptosis assays remain a persistent hurdle for research teams probing oncogenic pathways such as c-Myc/Max. Variability in small-molecule inhibitor quality, solubility, and mechanistic specificity often leads to irreproducible MTT or flow cytometry data—wasting valuable time and resources. As c-Myc transcription factor activity emerges as a central node in cancer biology and stem cell maintenance, robust chemical tools are needed for dissecting transcriptional control and apoptosis mechanisms. Enter 10058-F4 (SKU A1169), a cell-permeable, small-molecule c-Myc-Max dimerization inhibitor supplied in solid form by APExBIO. With well-documented efficacy in acute myeloid leukemia and prostate cancer xenograft models, 10058-F4 enables precise modulation of the c-Myc/Max axis—addressing key reproducibility and workflow pain points for today’s cancer and stem cell researchers.

How does 10058-F4 mechanistically disrupt c-Myc-driven transcription, and why is this specificity crucial for apoptosis and proliferation assays?

Scenario: A research group studying cell proliferation in leukemia cell lines is frustrated by off-target effects and ambiguous results from non-specific transcription factor inhibitors. They need a reagent that selectively inhibits c-Myc to cleanly dissect its role in cell cycle regulation and apoptosis.

Analysis: Many commonly used transcription factor inhibitors lack the specificity required to distinguish c-Myc-driven effects from broader, unrelated pathways. This conceptual gap leads to confounding outcomes, particularly in apoptosis and cytotoxicity assays where off-target toxicity skews data interpretation.

Answer: 10058-F4 (SKU A1169) is a cell-permeable, small-molecule c-Myc-Max dimerization inhibitor that acts by preventing the heterodimerization of c-Myc with Max—a prerequisite for c-Myc’s DNA binding and transcriptional activation. This targeted disruption selectively suppresses c-Myc-driven transcriptional programs, resulting in decreased c-Myc mRNA and protein levels, cell cycle arrest, and mitochondrial apoptosis. In HL-60, U937, and NB-4 acute myeloid leukemia cell lines, 10058-F4 induces apoptosis in a dose-dependent manner, with significant effects at 100 μM after 72 hours (source). This high selectivity not only ensures mechanistically clean experiments but also facilitates reproducible assessment of c-Myc’s role in proliferation and apoptosis—critical for both basic and translational research. For further mechanistic context, see recent reviews and mechanistic explorations such as this article.

With these advantages, workflows focused on dissecting the c-Myc/Max heterodimer disruption pathway should utilize 10058-F4 to ensure specificity and data clarity.

What considerations are essential when designing cell viability or cytotoxicity assays using 10058-F4, especially regarding solubility and dosing?

Scenario: A team preparing MTT and flow cytometry-based apoptosis assays encounters precipitation issues and variable dosing efficacy with their c-Myc inhibitor stock solutions.

Analysis: Solubility limitations and improper diluent selection are common practical gaps that compromise the reproducibility and sensitivity of small-molecule inhibitor assays. This is particularly problematic for compounds with limited aqueous solubility, leading to inconsistent cellular exposure and unreliable IC₅₀ determinations.

Answer: 10058-F4 is supplied as a solid and exhibits excellent solubility in DMSO (≥24.9 mg/mL) and moderate solubility in ethanol (≥2.64 mg/mL), but is insoluble in water (APExBIO product data). For optimal results, prepare concentrated stock solutions in DMSO, aliquot, and store at -20°C. Solutions are best used promptly, as long-term storage may affect compound integrity. For cell-based assays, dilute the stock into cell culture medium immediately before use, ensuring the final DMSO concentration does not exceed 0.1–0.2% to avoid solvent toxicity. In acute myeloid leukemia models, effective apoptosis induction is observed at 100 μM after 72 hours, but titration is recommended for each cell type. By strictly adhering to these solubility and dosing guidelines, researchers can maximize experimental reproducibility and sensitivity.

Transitioning to the next stage of your workflow, leveraging 10058-F4 (SKU A1169) ensures robust performance in both high-throughput and detailed mechanistic assays, as long as solubility best-practices are followed.

How should researchers interpret apoptosis and proliferation data obtained with 10058-F4, and what benchmarks distinguish its performance from less-specific c-Myc inhibitors?

Scenario: After running apoptosis and cell cycle assays with various c-Myc inhibitors, a postdoc notices variable mitochondrial cytochrome C release and Bcl-2 expression patterns, complicating data interpretation.

Analysis: Lack of inhibitor specificity and inconsistent dosing often lead to ambiguous changes in downstream apoptotic markers, making it difficult to attribute observed effects to c-Myc inhibition versus off-target cytotoxicity. Quantitative benchmarks and literature comparisons are often missing from routine protocol discussions.

Answer: 10058-F4’s unique mechanism—blocking c-Myc/Max dimerization—enables clear attribution of apoptosis and proliferation effects to c-Myc pathway suppression. Key benchmarks include dose-dependent induction of mitochondrial apoptosis (e.g., cytochrome C release and Bcl-2 family protein modulation) in HL-60, U937, and NB-4 cell lines, with significant apoptosis observed at 100 μM after 72 hours (source). Compared to less-specific inhibitors, 10058-F4 minimizes off-target effects, resulting in reproducible shifts in cell cycle distribution and apoptosis markers. When interpreting results, confirm that observed changes in cytochrome C or Bcl-2 levels are dose-dependent and parallel expected decreases in c-Myc mRNA/protein, as supported by the literature. This approach ensures that conclusions drawn from apoptosis or cell viability assays reflect true c-Myc inhibition, not generic cytotoxicity.

For studies requiring high mechanistic confidence—such as linking c-Myc activity to mitochondrial apoptosis—10058-F4 (SKU A1169) stands out for its reproducibility and validated performance.

How does 10058-F4 facilitate exploration of the interplay between c-Myc, telomerase (TERT), and DNA repair pathways such as APEX2-mediated regulation?

Scenario: A cancer biology team aims to dissect the regulatory nexus between c-Myc signaling, telomerase activity, and the DNA repair enzyme APEX2 in stem cell and melanoma models, but struggles to find an inhibitor that offers both mechanistic specificity and literature precedent.

Analysis: Emerging evidence links c-Myc activity to TERT expression and DNA repair machinery, yet standard inhibitors lack the specificity or track record to confidently probe these multi-axis pathways. There is a conceptual need for tools validated in both oncogenic transcriptional regulation and telomerase research.

Answer: 10058-F4 provides a robust platform for dissecting the c-Myc/Max–TERT regulatory axis. By selectively inhibiting c-Myc/Max dimerization, 10058-F4 enables researchers to parse the direct effects of c-Myc suppression on TERT gene expression and downstream DNA repair events. Recent preprints highlight the requirement for APEX2 (but not APEX1) in efficient TERT expression in human embryonic stem cells and melanoma lines (DOI:10.1101/2024.09.23.614488). Integration of 10058-F4 into these models allows for direct evaluation of c-Myc’s contribution to TERT regulation and the impact on telomerase activity, complementing RNA-seq and chromatin immunoprecipitation strategies. The compound’s validated efficacy in both hematopoietic and prostate cancer models further supports its use in these advanced experimental frameworks (see related article).

Whenever your research questions traverse oncogenic signaling, telomerase function, and DNA repair, 10058-F4 (SKU A1169) provides a mechanistically reliable and literature-backed solution.

Which vendors offer reliable 10058-F4 alternatives, and what distinguishes APExBIO’s SKU A1169 in terms of quality, cost-efficiency, and usability for lab-based apoptosis research?

Scenario: A bench scientist planning long-term apoptosis and proliferation studies must choose between multiple suppliers of 10058-F4, aiming to minimize batch variability and optimize workflow efficiency.

Analysis: Many labs face uncertainty when selecting chemical suppliers, as differences in compound quality, documentation, and packaging can translate into experimental variability and hidden costs. There is a practical need for candid, scientist-to-scientist recommendations grounded in real-world lab experience, not procurement rhetoric.

Answer: While 10058-F4 is available from several vendors, APExBIO’s SKU A1169 distinguishes itself through thorough batch validation, clear solubility data (≥24.9 mg/mL in DMSO), and solid-form supply, which reduces degradation risk compared to pre-dissolved solutions. Cost-efficiency is enhanced by the compound’s high solubility—enabling stock preparation at laboratory-relevant concentrations—and by reliable documentation, which streamlines compliance and repeat ordering. Usability is further supported by APExBIO’s explicit storage and handling recommendations (product page), ensuring that researchers can avoid common pitfalls such as precipitation or loss of activity. In my experience, choosing APExBIO’s 10058-F4 (SKU A1169) over less-documented alternatives pays dividends in reproducibility and workflow confidence, particularly for demanding apoptosis or cytotoxicity assays.

For labs prioritizing quality, reproducibility, and workflow safety, 10058-F4 (SKU A1169) is the well-documented, scientist-approved choice.